300534.SZ Stock Analysis
30
Neutral
Based on Eyestock quantitative analysis, 300534.SZ`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly undervalued
Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. engages in the research and development of pharmaceutical, medical and health care products; and production and sale of Chinese patent medicines, health foods, and raw materials. The company is headquartered in Lanzhou, Gansu and currently employs 302 full-time employees. The company went IPO on 2016-09-13. The firm operates two segments. The Pharmaceutical Manufacturing segments is involved in the production and sale of Chinese traditional medicine, health food and raw materials. Its primary product is Yuanhuzhitong dripping pills, which is used for the treatment of stomach pain, rib pain and headache. The firm also produces other drugs, including compound salvia miltiorrhiza tablets, anti-inflammatory and gallbladder tablets, as well as Sanqi injury tablets. The Sales and Logistics segment operates logistics and distribution business.